Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory/relapsed AML: Case report and exploration of possible mechanisms

Venetoclax, a selective BCL-2 inhibitor, has shown superior efficacy in the treatment of AML. Nevertheless, some AML patients with <i>AML1-ETO</i> respond poorly to venetoclax treatment. In this report, a relapsed/refractory (R/R) venetoclax resistant <i>AML1-ETO</i> positive AML patient showed rapid tumor regression after combination therapy with gilteritinib and venetoclax. Additional laboratory findings indicated that the combined impact of the two drugs may be associated with the induction of the integrated stress response. This case presents a novel therapeutic approach for the treatment of FLT3 wild-type RR, <i>AML1-ETO</i> AML patients who have primary resistance to venetoclax.

Authors

Institutions

Publication Details

Journal
Heliyon
Published
2024-08-01
DOI
https://doi.org/10.1016/j.heliyon.2024.e35847
Citations
3
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
1.36

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory/relapsed AML: Case report and exploration of possible mechanisms

Yaonan Hong, Dijiong Wu, Guoyin Kai, Tonglin Hu et al.
3 citations
Heliyon
Acute Myeloid Leukemia Research
1.36
article

Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory/relapsed AML: Case report and exploration of possible mechanisms

Yaonan Hong, Dijiong Wu, Guoyin Kai, Tonglin Hu, Yiping Shen, Qi Liu, Xiawan Yang, Yingying Shen, Man Li
article en
3 citations

Abstract

Venetoclax, a selective BCL-2 inhibitor, has shown superior efficacy in the treatment of AML. Nevertheless, some AML patients with <i>AML1-ETO</i> respond poorly to venetoclax treatment. In this report, a relapsed/refractory (R/R) venetoclax resistant <i>AML1-ETO</i> positive AML patient showed rapid tumor regression after combination therapy with gilteritinib and venetoclax. Additional laboratory findings indicated that the combined impact of the two drugs may be associated with the induction of the integrated stress response. This case presents a novel therapeutic approach for the treatment of FLT3 wild-type RR, <i>AML1-ETO</i> AML patients who have primary resistance to venetoclax.

HeliyonVol. 10(16)
Zhejiang Chinese Medical University (CN), Wenzhou Hospital of Traditional Chinese Medicine (CN)
Guangxi Key Laboratory of Traditional Chinese Medicine Quality Standards Research, National Natural Science Foundation of China, National Aerospace Science Foundation of China, First Affiliated Hospital of Zhengzhou University, Natural Science Foundation of Shaanxi Provincial Department of Education, Natural Science Foundation of Zhejiang Province, Zhejiang Xinmiao Talents Program, Science and Technology Program of Zhejiang Province
Zero hunger
Openalex Percentile: Top 18%
Acute Myeloid Leukemia Research
1.36
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.